Evotec (ETR:EVT) has been assigned a €20.00 ($23.26) target price by stock analysts at Berenberg Bank in a report issued on Wednesday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. Berenberg Bank’s price objective would indicate a potential downside of 13.53% from the company’s current price.
Separately, Deutsche Bank set a €23.00 ($26.74) price target on Evotec and gave the stock a “neutral” rating in a research report on Friday, May 17th.
Shares of EVT opened at €23.13 ($26.90) on Wednesday. The company has a current ratio of 1.27, a quick ratio of 1.18 and a debt-to-equity ratio of 26.94. Evotec has a 1 year low of €12.18 ($14.16) and a 1 year high of €25.83 ($30.03). The stock has a market cap of $3.44 billion and a price-to-earnings ratio of 41.30.
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Featured Article: Percentage Decliners
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.